Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

November 19, 2021 Auto Bot Jazz, narcolepsy, NICE, Recommendation, regulatory 0

Shots:

  • NICE has issued a positive Final Appraisal Document which recommends Sunosi (75/150mg, qd) as an option treatment for adults with EDS caused by narcolepsy with/out cataplexy. The therapy will be available in England and Wales
  • The recommendation is based on the P-III TONES studies to evaluate Sunosi vs PBO in adults patients with EDS. The results demonstrated a clinical effectiveness and safety profile of solriamfetol in patients with narcolepsy & maintain its effect after 6mos. of treatment
  • Solriamfetol is dual-acting dopamine and noradrenaline reuptake inhibitor & is designed to improve wakefulness and reduce EDS in adult patients with narcolepsy

Click here to­ read full press release/ article | Ref: Jazz  | Image: Jazz

The post Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy first appeared on PharmaShots.